FDA updates pembrolizumab’s tumor-mutation indication with traditional approval — sources for revision 1
U.S. Food and Drug Administration
Source date: 2026-10-22.
Supporting location: Opening October16approvalparagraph and paragraph explaining conversion fromacceleratedapproval andthresholdchange10to13mut/Mb..
Source dates are distinct from Iliyn’s preparation date. Source statements do not independently prove underlying events. No full source articles or source photographs are reproduced.